Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35711093/
A mild eGFR decrease may be expected after the initiation of empagliflozin, and it is not associated with untoward HF, mortality or kidney safety events. Clinicians should not be concerned...
Conclusion: A mild eGFR decrease may be expected after the initiation of empagliflozin, and it is not associated with untoward HF, mortality or kidney safety events. Clinicians should not be concerned with early eGFR changes post-initiation of empagliflozin. This article is protected by copyright. All rights reserved.
Beta-blockers are associated with increased B-type natriuretic peptide levels differently in men and women in heart failure with preserved ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35714176/
Beta-blocker (BB) use is a mainstay for treatment of heart failure (HF) with reduced ejection fraction (HFrEF), whereas its efficacy for heart failure with preserved ejection fraction (HFpEF) remains controversial....
Conclusion: BB use was associated with high plasma BNP levels and lower LVEF in women but not in men with HFpEF and SR, suggesting that the pathogenesis and of HFpEF may differ in men and women in SR.
Effects of SGLT2 inhibitors on cardiac structure and function - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35711023/
SGLT2 inhibitors reduce cardiovascular death or hospitalization for heart failure, regardless of the presence or absence of diabetes in patients at high cardiovascular risk and in those with heart failure...
Conclusion/Relevance: SGLT2 inhibitors reduce cardiovascular death or hospitalization for heart failure, regardless of the presence or absence of diabetes in patients at high cardiovascular risk and in those with heart failure and reduced ejection fraction (HFrEF).
Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
Source : https://www.sciencedirect.com/science/article/pii/S221317792200302X?via=ihub
N-terminal pro-B type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) are associated with disease severity and outcomes among patients with heart failure with preserved ejection fraction (HFpEF). We...
Conclusions: The benefit of empagliflozin on cardiac outcomes and decline of eGFR is preserved across the wide range of baseline NT-proBNP and hs-cTnT evaluated. Empagliflozin modestly reduces NT-proBNP in HFpEF.
Comorbidities in heart failure with preserved ejection fraction - Herz
Source : https://link.springer.com/article/10.1007/s00059-022-05123-9
Chronic heart failure is one of the most common causes of hospitalization and death in industrialized countries. Demographic changes with an aging population are expected to further increase the prevalence...
Conclusion/Relevance: Except for comorbidity-specific guidelines, no HFpEF-specific treatment of comorbidities can be recommended at this time. Optimized care is becoming increasingly relevant to reducing hospitalizations through a seamless inpatient and outpatient care structure. Current treatment is focused on symptom relief and management of...